Financials CellaVision AB

Equities

CEVI

SE0000683484

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 12:00:00 2024-07-12 pm EDT 5-day change 1st Jan Change
274.5 SEK +1.48% Intraday chart for CellaVision AB +11.59% +29.48%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,621 7,322 7,757 5,462 5,057 6,547 - -
Enterprise Value (EV) 1 7,678 7,353 7,763 5,456 5,000 6,421 6,333 6,181
P/E ratio 76.8 x 81.9 x 61.9 x 46.2 x 38.8 x 39.4 x 30.3 x 24 x
Yield - 0.24% 0.62% 0.87% 1.06% 0.89% 1.08% 1.29%
Capitalization / Revenue 16.5 x 15.5 x 13.7 x 8.54 x 7.47 x 8.48 x 7.37 x 6.35 x
EV / Revenue 16.6 x 15.6 x 13.7 x 8.53 x 7.38 x 8.31 x 7.13 x 6 x
EV / EBITDA 52.3 x 51.5 x 39.6 x 27.5 x 24.2 x 25.1 x 20.2 x 16.2 x
EV / FCF 72.3 x 117 x 68 x 81.1 x 45.1 x 43.4 x 38.9 x 30 x
FCF Yield 1.38% 0.86% 1.47% 1.23% 2.22% 2.31% 2.57% 3.34%
Price to Book 21.9 x 17 x 14.3 x 8.51 x 7.06 x 7.88 x 6.7 x 5.47 x
Nbr of stocks (in thousands) 23,852 23,852 23,852 23,852 23,852 23,852 - -
Reference price 2 319.5 307.0 325.2 229.0 212.0 274.5 274.5 274.5
Announcement Date 2/5/20 2/4/21 2/4/22 2/8/23 2/7/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 461.8 471.4 565.6 639.3 677.3 772.2 887.9 1,030
EBITDA 1 146.7 142.9 196.2 198.4 206.8 256.2 313 381.7
EBIT 1 126.6 110.3 162.7 158.3 167.1 213 271.2 339.2
Operating Margin 27.41% 23.39% 28.77% 24.75% 24.66% 27.58% 30.54% 32.92%
Earnings before Tax (EBT) 1 129.2 112.2 158.3 148.4 164.2 211.2 273.7 345.7
Net income 1 99.17 89.48 125.3 118.3 130.3 166.6 216.3 272.9
Net margin 21.48% 18.98% 22.16% 18.51% 19.24% 21.58% 24.36% 26.48%
EPS 2 4.160 3.750 5.250 4.960 5.460 6.973 9.055 11.44
Free Cash Flow 1 106.2 63.06 114.2 67.27 110.9 148 162.8 206.3
FCF margin 23.01% 13.37% 20.19% 10.52% 16.37% 19.16% 18.33% 20.02%
FCF Conversion (EBITDA) 72.4% 44.13% 58.21% 33.91% 53.62% 57.78% 52% 54.06%
FCF Conversion (Net income) 107.12% 70.47% 91.11% 56.85% 85.11% 88.81% 75.26% 75.61%
Dividend per Share 2 - 0.7500 2.000 2.000 2.250 2.433 2.977 3.550
Announcement Date 2/5/20 2/4/21 2/4/22 2/8/23 2/7/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 164.2 162.4 183.6 141 152.3 139.1 169.7 167.9 200.6 170.1 192 193 224.7
EBITDA 1 60.49 59.04 61.48 29.45 48.4 34.55 56.03 43.44 72.79 49.26 63.57 66.3 84.73
EBIT 1 51.76 49.82 52.43 16.96 39.06 25.04 46.19 33.27 62.55 38.82 53.29 55.32 73.78
Operating Margin 31.53% 30.67% 28.56% 12.02% 25.65% 18% 27.23% 19.82% 31.18% 22.82% 27.75% 28.66% 32.84%
Earnings before Tax (EBT) 1 51.04 48.62 46.86 12.85 40.09 24.36 44.34 32.16 63.37 38.24 53.5 51.36 75.26
Net income 1 39.76 38.4 37.25 10.38 32.3 19.21 34.71 25.96 50.43 30.12 42.44 42.89 58.38
Net margin 24.22% 23.64% 20.29% 7.36% 21.2% 13.81% 20.46% 15.46% 25.14% 17.71% 22.1% 22.22% 25.98%
EPS 2 1.670 1.610 1.560 0.4400 1.350 0.8100 1.460 1.090 2.110 1.260 1.749 1.805 2.453
Dividend per Share 2 - - - - - - - - - - - - 2.300
Announcement Date 2/4/22 5/10/22 7/20/22 10/26/22 2/8/23 5/4/23 7/20/23 10/25/23 2/7/24 4/25/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 57.8 30.5 6.37 - - - - -
Net Cash position 1 - - - 5.56 56.9 127 214 367
Leverage (Debt/EBITDA) 0.3936 x 0.2136 x 0.0325 x - - - - -
Free Cash Flow 1 106 63.1 114 67.3 111 148 163 206
ROE (net income / shareholders' equity) 31.1% 23% 25.8% 20% 19.2% 21.4% 23.6% 24.6%
ROA (Net income/ Total Assets) - - - 13.8% 14.3% - - -
Assets 1 - - - 858.5 910.2 - - -
Book Value Per Share 2 14.60 18.00 22.80 26.90 30.00 34.90 41.00 50.20
Cash Flow per Share - 2.980 - - - - - -
Capex 1 2.67 8.07 84.3 70 85.5 88 91 93.7
Capex / Sales 0.58% 1.71% 14.91% 10.95% 12.63% 11.4% 10.25% 9.09%
Announcement Date 2/5/20 2/4/21 2/4/22 2/8/23 2/7/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
274.5 SEK
Average target price
256.2 SEK
Spread / Average Target
-6.65%
Consensus
  1. Stock Market
  2. Equities
  3. CEVI Stock
  4. Financials CellaVision AB